Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. (NASDAQ: CYRX) on May 14, 2019. The filing reports the entry into and immediate completion of a Material Definitive Agreement involving the acquisition of assets from CryoGene Partners (d/b/a Cryogene Labs).
Key Financial Metrics and Transaction Details
- Transaction Type: Asset Purchase Agreement.
- Target Entity: CryoGene Partners (Seller), a Texas general partnership.
- Acquirer: Cryogene, Inc., a wholly owned subsidiary of Cryoport, Inc.
- Purchase Price: $20.5 million in cash (Total Consideration).
- Escrow: $1 million of the purchase price is held in escrow for indemnifiable losses.
- Target Revenue History: Approximately $3.9 million in 2018 and $3.4 million in 2017.
- Assets Acquired: Tangible personal property, intellectual property, inventory, and contracts related to temperature-controlled biostorage and biobanking solutions in Houston, Texas.
Material Changes and Strategic Impact
The transaction closed simultaneously with the execution of the agreement on May 14, 2019. Management expects the acquisition to be immediately accretive to Cryoport's earnings. The filing does not provide specific consolidated financial metrics (revenue, profit, cash flow, or debt) for Cryoport, Inc. for the current period, as this is a current report focused on a specific event rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Forward-Looking Statements: The filing includes statements regarding expected benefits and earnings accretion, which are subject to risks and uncertainties.
- Risk Factors: Investors are directed to the "Risk Factors" section of Cryoport's most recent Form 10-K for details on uncertainties that could cause actual results to differ materially.
- Indemnification: The agreement includes customary indemnification rights for breaches of representations, warranties, and covenants, subject to deductibles and caps.
- Covenants: The Seller has agreed to non-competition and non-solicitation covenants.
- Missing Data: Pro forma financial information and detailed financial statements of the business acquired are not included in this filing; they are scheduled to be filed via amendment within 71 days.
Key Facts for Investor Verification
- Verify the immediate accretive impact on earnings as claimed by management once pro forma data is filed.
- Review the full Asset Purchase Agreement (Exhibit 2.1) for specific indemnification caps and deductibles.
- Monitor the upcoming amendment to this 8-K for the required financial statements of the acquired business and pro forma information.
- Confirm the integration timeline for the Houston-based biostorage assets into Cryoport's existing operations.